m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02905)
Name
CS-038
Synonyms
Chiglitazar; CS-00098; PPAR alpha/gamma agonist (diabetes), Chipscreen Biosciences
    Click to Show/Hide
Status
Phase 3
Structure
Formula
C36H29FN2O4
InChI
1S/C36H29FN2O4/c37-26-17-15-25(16-18-26)35(40)30-9-1-4-10-31(30)38-32(36(41)42)23-24-13-19-27(20-14-24)43-22-21-39-33-11-5-2-7-28(33)29-8-3-6-12-34(29)39/h1-20,32,38H,21-23H2,(H,41,42)/t32-/m0/s1
InChIKey
QNLWMPLUWMWDMQ-YTTGMZPUSA-N
PubChem CID
71402018
TTD Drug ID
D0F5JH
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Peroxisome proliferator-activated receptor alpha (PPARA)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CS-038. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of CS-038 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CS-038. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CS-038 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). [2], [3]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CS-038. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CS-038 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). [2], [4]
Wilms tumor 1-associating protein (WTAP)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CS-038. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of CS-038 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). [2], [3]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CS-038. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CS-038 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). [2], [4]
Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Peroxisome proliferator-activated receptor gamma (PPAR-gamma) is a therapeutic target for CS-038. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of CS-038 through regulating the expression of Peroxisome proliferator-activated receptor gamma (PPAR-gamma). [2], [5]
References
Ref 1 Resveratrol Attenuates High-Fat Diet Induced Hepatic Lipid Homeostasis Disorder and Decreases m(6)A RNA Methylation. Front Pharmacol. 2020 Dec 18;11:568006. doi: 10.3389/fphar.2020.568006. eCollection 2020.
Ref 2 Tesaglitazar, a dual PPAR-Alpha/Gamma agonist, hamster carcinogenicity, investigative animal and clinical studies. Toxicol Pathol. 2012;40(1):18-32. doi: 10.1177/0192623311429972. Epub 2011 Nov 30.
Ref 3 A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014 Feb;10(2):93-5. doi: 10.1038/nchembio.1432. Epub 2013 Dec 6.
Ref 4 Circadian Clock Regulation of Hepatic Lipid Metabolism by Modulation of m(6)A mRNA Methylation. Cell Rep. 2018 Nov 13;25(7):1816-1828.e4. doi: 10.1016/j.celrep.2018.10.068.
Ref 5 The m(6)A demethylase FTO promotes the osteogenesis of mesenchymal stem cells by downregulating PPARG. Acta Pharmacol Sin. 2022 May;43(5):1311-1323. doi: 10.1038/s41401-021-00756-8. Epub 2021 Aug 30.